19th Mar 2020 12:44
(Alliance News) - Physiomics PLC said Thursday its pipeline remains strong despite the Covid-19 outbreak, but is worried about a delay to its ongoing cancer study.
The study is for further development of and evidence generation for a precision dosing tool for optimising chemotherapy dosing in advanced prostate cancer. Physiomics expects it to delay due to the measures being taken by all hospitals in the UK to minimise non-Covid-19 related activity.
"Even were this to materialise, the board believes that it is currently trading in line with market expectations for the current financial year based on current assumptions around the impact of Covid-19," the company added.
Physiomics said its "strong" pipeline will keep it busy until its year-end on June 30.
Physiomics added: "The company will continue to closely monitor the UK Government's advice in relation to Covid-19, as well as the possibly impact on clients in other countries and provide further updates to shareholders as and when appropriate. In the meantime, the company would like to wish its clients and shareholders a safe and healthy few months as this event unfolds."
Shares in Physiomics were down 3.8% in London on Thursday afternoon at 1.54 pence each.
By Paul McGowan; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
Physiomics